Apr 08, 2020 8:30am EDT Medexus Reports Triamcinolone Hexacetonide Injectable Suspension Approved for Public Reimbursement in Canada
Mar 23, 2020 8:30am EDT Medexus Provides a Business Update and Outlines Response to COVID-19 Pandemic
Feb 28, 2020 8:59am EST Medexus Expands its US Product Portfolio by Acquiring the Hematology Asset IXINITY®
Feb 18, 2020 6:52pm EST Medexus Pharmaceuticals Reports Revenue of $16.2 Million for the Third Quarter of Fiscal 2020
Nov 29, 2019 5:00pm EST Medexus Pharmaceuticals Reports Operating and Financial Results for the Second Quarter of Fiscal 2020
Oct 22, 2019 9:00am EDT Medexus Pharmaceuticals to Present at the Dawson James Securities 5th Annual Small Cap Growth Conference
